BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study
BioCardia Inc (NASDAQ:BCDA) presented detailed echocardiography data from the roll-in cohort of the Phase 3 CardiAMP Cell Therapy Heart Failure Trial.…
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades.
Dawson James Downgrades BioCardia to Neutral
Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.
Earnings Preview For BioCardia
BioCardia (NASDAQ:BCDA) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement.
Analysts estimate that BioCardia will report an earnings per share (EPS) of $-0.23.
BioCardia’s Heart Failure Cell Therapy Shows 100% Survival At Two Years
BioCardia Inc (NASDAQ:BCDA) announced data from its CardiAMP Cell Therapy for Heart Failure pivotal trial. “The two-year outcomes for patients with…
BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data At HFSA Annual Meeting
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough
BioCardia Announces CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data To Be Presented At Heart Failure Society Of America Annual Meeting
Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today
BioCardia Enters Agreement with BlueRock Therapeutics To Provide Enabling Catheter Biotherapeutic Delivery Product Candidates For BlueRock’s Cell Therapy To Treat Heart Failure
BioCardia®, Inc. (NASDAQ:BCDA), today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock's cell therapy product candidates for the treatment of
BioCardia Q2 EPS $(0.14) Beats $(0.25) Estimate, Sales $974.00K Up From $69.00K YoY
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.25) by 44 percent. This is a 30 percent increase over losses of $(0.20) per share from the same